Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > IMMU type buyout takes us to $220/share

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Jul 24, 2022 4:51pm

113 Views

Post# 34846613

RE:RE:RE:IMMU type buyout takes us to $220/share

It needs more science but the theory goes there's less Sortilin expression at earlier cancer stages. If that holds out I don't see the drug getting approval without Sortilin pre-screening so it won't exactly replace docetaxel.

stockman75 wrote: I have wondered the same regarding earlier stage treatment. If it works better with less side effects it seems it would have to be used at earlier stage. No?

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (June 28, 2024)